Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients.

Düring S, Glenthøj BY, Andersen GS, Oranje B.

Neuropsychopharmacology. 2014 Dec;39(13):3000-8. doi: 10.1038/npp.2014.152. Epub 2014 Jul 23.

2.

Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients.

Düring S, Glenthøj BY, Oranje B.

Int J Neuropsychopharmacol. 2015 Oct 9;19(3):pyv109. doi: 10.1093/ijnp/pyv109.

3.

Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine.

Quednow BB, Wagner M, Westheide J, Beckmann K, Bliesener N, Maier W, Kühn KU.

Biol Psychiatry. 2006 Mar 15;59(6):536-45. Epub 2005 Sep 1.

PMID:
16139819
4.

Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months' treatment with quetiapine.

Aggernaes B, Glenthoj BY, Ebdrup BH, Rasmussen H, Lublin H, Oranje B.

Int J Neuropsychopharmacol. 2010 Nov;13(10):1383-95. doi: 10.1017/S1461145710000787. Epub 2010 Jul 16.

PMID:
20633319
5.

Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels.

Csomor PA, Stadler RR, Feldon J, Yee BK, Geyer MA, Vollenweider FX.

Neuropsychopharmacology. 2008 Feb;33(3):497-512. Epub 2007 Apr 25.

6.

Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.

Csomor PA, Preller KH, Geyer MA, Studerus E, Huber T, Vollenweider FX.

Neuropsychopharmacology. 2014 Sep;39(10):2485-96. doi: 10.1038/npp.2014.102. Epub 2014 May 7.

7.
8.

Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia.

Quednow BB, Frommann I, Berning J, Kühn KU, Maier W, Wagner M.

Biol Psychiatry. 2008 Nov 1;64(9):766-73. doi: 10.1016/j.biopsych.2008.04.019. Epub 2008 Jun 2.

9.

Repeated but not acute treatment with ∆⁹-tetrahydrocannabinol disrupts prepulse inhibition of the acoustic startle: reversal by the dopamine D₂/₃ receptor antagonist haloperidol.

Tournier BB, Ginovart N.

Eur Neuropsychopharmacol. 2014 Aug;24(8):1415-23. doi: 10.1016/j.euroneuro.2014.04.003. Epub 2014 May 4.

PMID:
24846537
10.

P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment.

Oranje B, Aggernaes B, Rasmussen H, Ebdrup BH, Glenthøj BY.

Schizophr Bull. 2013 Mar;39(2):472-80. doi: 10.1093/schbul/sbr183. Epub 2012 Jan 12.

11.

Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients.

Brockhaus-Dumke A, Schultze-Lutter F, Mueller R, Tendolkar I, Bechdolf A, Pukrop R, Klosterkoetter J, Ruhrmann S.

Biol Psychiatry. 2008 Sep 1;64(5):376-84. doi: 10.1016/j.biopsych.2008.02.006. Epub 2008 Apr 8.

PMID:
18395700
12.

Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia.

Hong X, Chan RC, Zhuang X, Jiang T, Wan X, Wang J, Xiao B, Zhou H, Jiang L, Weng B.

Schizophr Res. 2009 Mar;108(1-3):151-7. doi: 10.1016/j.schres.2008.11.016. Epub 2008 Dec 23.

PMID:
19106034
13.

Differential effects of acute serotonin and dopamine depletion on prepulse inhibition and p50 suppression measures of sensorimotor and sensory gating in humans.

Mann C, Croft RJ, Scholes KE, Dunne A, O'Neill BV, Leung S, Copolov D, Phan KL, Nathan PJ.

Neuropsychopharmacology. 2008 Jun;33(7):1653-66. Epub 2007 Sep 26.

14.

Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients.

Boutros NN, Brockhaus-Dumke A, Gjini K, Vedeniapin A, Elfakhani M, Burroughs S, Keshavan M.

Schizophr Res. 2009 Sep;113(2-3):339-46. doi: 10.1016/j.schres.2009.05.019. Epub 2009 Jun 12.

15.

Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.

Wulff S, Pinborg LH, Svarer C, Jensen LT, Nielsen MØ, Allerup P, Bak N, Rasmussen H, Frandsen E, Rostrup E, Glenthøj BY.

Schizophr Bull. 2015 Sep;41(5):1143-52. doi: 10.1093/schbul/sbu220. Epub 2015 Feb 18.

16.

Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers.

Petrovsky N, Quednow BB, Ettinger U, Schmechtig A, Mössner R, Collier DA, Kühn KU, Maier W, Wagner M, Kumari V.

Neuropsychopharmacology. 2010 Jun;35(7):1429-39. doi: 10.1038/npp.2010.12. Epub 2010 Mar 10.

17.

Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively.

Riba J, Rodríguez-Fornells A, Barbanoj MJ.

Psychopharmacology (Berl). 2002 Dec;165(1):18-28. Epub 2002 Oct 12.

PMID:
12474114
18.

The neurosteroidogenic enzyme 5α-reductase modulates the role of D1 dopamine receptors in rat sensorimotor gating.

Frau R, Mosher LJ, Bini V, Pillolla G, Pes R, Saba P, Fanni S, Devoto P, Bortolato M.

Psychoneuroendocrinology. 2016 Jan;63:59-67. doi: 10.1016/j.psyneuen.2015.09.014. Epub 2015 Sep 24.

19.

Association study of polymorphisms in the alpha 7 nicotinic acetylcholine receptor subunit and catechol-o-methyl transferase genes with sensory gating in first-episode schizophrenia.

Liu X, Hong X, Chan RC, Kong F, Peng Z, Wan X, Wang C, Cheng L.

Psychiatry Res. 2013 Oct 30;209(3):431-8. doi: 10.1016/j.psychres.2013.03.027. Epub 2013 Apr 15.

PMID:
23598060
20.

MEG does not reveal impaired sensory gating in first-episode schizophrenia.

Bachmann S, Weisbrod M, Röhrig M, Schröder J, Thomas C, Scherg M, Rupp A.

Schizophr Res. 2010 Aug;121(1-3):131-8. doi: 10.1016/j.schres.2010.03.007. Epub 2010 May 5.

PMID:
20447805

Supplemental Content

Support Center